XML 187 R44.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Shareholders (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2025

Dec. 31, 2024

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and dilutive net loss per share:


	Three Months Ended March 31,
(Amounts in thousands, except share and per share amounts)	2025			2024
Numerator:
Net loss	$	(147,761	)	$	(16,743	)
Denominator:
Weighted average number of shares outstanding, basic and diluted		91,747,685			13,613,270

Net loss per share, basic and diluted	$	(1.61	)	$	(1.23	)

The following table sets forth the computation of basic and dilutive net loss per share attributable to common stockholders for the years ended December 31, 2024 and 2023:


	2024			2023
Numerator:
Net loss	$	(61,195	)	$	(87,589	)
Net loss
Denominator:
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted		17,476,105			4,213,244

Net loss per share attributable to common stockholders, basic and diluted	$	(3.50	)	$	(20.79	)

Schedule Of Potentially Dilutive Securities

The following potentially

dilutive

securities were excluded from the calculation of diluted net loss per share attributable to common shareholders for the periods presented because the impact of including them would have been anti-dilutive for the years ended December 31, 2024 and 2023:


	2024			2023
Redeemable convertible preferred stock		44,494,703			44,494,703
Stock options		36,363,184			16,437,980
Restricted stock units		4,655,274			4,916,829
Series D and D-2 preferred stock warrants		756,172			1,094,667
Pay-to-Play warrants (estimated See Note 8)		1,127,088			721,086
Convertible Notes warrants - 2023			(a)			(a)
Common stock warrants		—			2,063
Pre-funded warrant (estimated See Note 8)		2,000,000			7,007,582
Pre-funded warrant April 2024 (estimated See Note 8)		4,500,000			—

Total potentially dilutive shares		93,896,421			74,674,910

(a)	The number of warrants shares to be issued upon exercise of the 2023 Convertible Note Warrants is not determinable due to the variable settlement terms (see Note 8).